clinical trial · NCT02486640
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Bayer·—·completed·n = 162
Multiple SclerosisInterferon beta-1b (Betaferon, BAY86-5046)Betaconnect Autoinjector
brief summary
This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
started
Sep 8, 2015
primary completion
Oct 31, 2019
completion
Jan 16, 2020
last updated
Jul 24, 2023
official title
BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol